Trelagliptin is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 2 investigational indications. Trelagliptin is a member of benzenes and a nitrile. It is grouped under the following drug class(es): DPP-4 inhibitors. Its therapeutic use is listed as antidiabetic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Trelagliptina and Trelagliptinum. Its PubChem CID is 15983988.
Trelagliptin
| CAS No | 865759-25-7 |
|---|---|
| Molecular Formula | C18H20FN5O2 |
| Molecular Weight | 357.4 g/mol |
| Synonyms | 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Trelagliptin is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 2 investigational indications.
The listed CAS number is 865759-25-7.
The listed molecular formula is C18H20FN5O2.
The listed molecular weight is 357.4 g/mol.
2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile.
The source lists Trelagliptina and Trelagliptinum.